Abstract:Transforming growth factor beta (TGF beta) is a secreted growth and differentiation factor that influences vital cellular processes like proliferation, adhesion, motility, and apoptosis. Regulation of the TGF beta signaling pathway is of key importance to maintain tissue homeostasis. Perturbation of this signaling pathway has been implicated in a plethora of diseases, including cancer. The effect of TGF beta is dependent on cellular context, and TGF beta can perform both anti- and pro-oncogenic roles. TGF beta acts by binding to specific cell surface TGF beta type I and type II transmembrane receptors that are endowed with serine/threonine kinase activity. Upon ligand-induced receptor phosphorylation, SMAD proteins and other intracellular effectors become activated and mediate biological responses. The levels, localization, and function of TGF beta signaling mediators, regulators, and effectors are highly dynamic and regulated by a myriad of post-translational modifications. One such crucial modification is ubiquitination. The ubiquitin modification is also a mechanism by which crosstalk with other signaling pathways is achieved. Crucial effector components of the ubiquitination cascade include the very diverse family of E3 ubiquitin ligases. This review summarizes the diverse roles of E3 ligases that act on TGF beta receptor and intracellular signaling components. E3 ligases regulate TGF beta signaling both positively and negatively by regulating degradation of receptors and various signaling intermediates. We also highlight the function of E3 ligases in connection with TGF beta's dual role during tumorigenesis. We conclude with a perspective on the emerging possibility of defining E3 ligases as drug targets and how they may be used to selectively target TGF beta-induced pro-oncogenic responses.

E3 Ubiquitin Ligases: Key Regulators of TGF Signaling in Cancer Progression

E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression

Key Role for Ubiquitin Protein Modification in TGFβ Signal Transduction

Regulation of TGF-beta signalling by protein phosphatases.

Regulation of the TGF-β Pathway by Deubiquitinases in Cancer.

The Regulation of TGF-β/SMAD Signaling by Protein Deubiquitination

E3 ubiquitin ligases as cancer targets and biomarkers.

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

Abstract IA33: Regulation of TGF-β receptor signaling in cancer

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy

To Ub or not to Ub: a regulatory question in TGF- signaling

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-β signaling

To Ub or not to Ub: a regulatory question in TGF-β signaling.

Targeting TGFβ signal transduction for cancer therapy

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-beta signaling.

Roles of Ubiquitination in the Crosstalk Between Tumors and the Tumor Microenvironment (Review)

Transforming growth factor-β receptors: versatile mechanisms of ligand activation

Transforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within

Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases

Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy